Introduction
Major depressive disorder (MDD) is one of the most prevalent mental disorder and is estimated to be the fourth leading cause of disease burden worldwide.
1,2 Pharmacotherapy is the primary choice for MDD. However, most antidepressants lacked efficacy and tolerability for patients with MDD, and adverse effects were the leading reasons of discontinuation during the treatment. 3, 4 Therefore, new antidepressants that can offer a greater advantage in efficacy and tolerability are needed. In this regard, levomilnacipran, which has a unique pharmacological activity compared with currently marketed serotonin-norepinephrine reuptake inhibitors (SNRIs), may prove to be an appealing alternative.
Levomilnacipran (1S, 2R-milnacipran) extended-release (ER), as the fourth SNRI, was approved by the US Food and Drug Administration (FDA) in July 2013 with doses of 40-120 mg capsule once daily. 5 In vitro studies have shown that levomilnacipran The efficacy and safety of levomilnacipran ER have been evaluated in several clinical studies, but the evaluation results were not completely consistent. A recent review had pooled the efficacy of levomilnacipran ER for MDD, using Cohen's d and number-needed-to-treat (NNT) as effect sizes, 8 which did not evaluate the safety of levomilnacipran ER and the effect on Sheehan Disability Scale (SDS). However, a significant improvement in SDS may demonstrate efficacy in treating functional impairment. 9 Thus, the aims of this article were to systematically review the existing published data regarding the treatment of MDD comparing levomilnacipran ER and placebo (including Montgomery-Åsberg Depression Rating Scale [MADRS] total score, SDS total score, response rate, remission rate, adverse effects, and cardiovascular effects) and to evaluate the efficacy and safety of levomilnacipran ER.
Methods

Data sources and search strategy
We searched PubMed, Embase, Medline, Ovid, the Cochrane Collaboration Library, Scopus and ScienceDirect, PsycInfo, and International Pharmaceutical Abstracts from inception to March 2016, without restriction of language. Potentially relevant unpublished data were searched by ClinicalTrials.gov, FDA website, European Union Drug Regulating Authorities Clinical Trials and the World Health Organization International Clinical Trials Registry Platform. We used the following terms: "levomilnacipran", "LVM", "fetzlma", "F2695", "major depressive disorder", "depression or major depression", and "MDD". These terms were adjusted to comply with the relevant rules in each database.
study election
Two investigators (QH and XZ) independently reviewed the title and abstract and selected randomized controlled trials of levomilnacipran ER for the treatment of MDD. All the studies met the following criteria: 1. All patients (18- 3. MADRS total score was used as the primary outcome in eligible studies. 4. Studies included one or more of the secondary outcomes: SDS total score, MADRS remission rate (total score 10), MADRS response rate (50% improvement from baseline), adverse events (AEs), and cardiovascular effects.
Full-text articles were retrieved independently by two investigators (QH and XZ). If they had a disagreement, the third investigator (YH) was used to solve the disagreement when necessary.
Data extraction
Data were extracted by two investigators (QH and XZ), and any discrepancies were resolved by consensus. For each study, two investigators (QH and XZ) extracted information on study characteristics, participants' baseline characteristics, interventions of the trial, end points, and findings.
Quality assessment
Two investigators (QH and XZ) assessed the quality of included studies by using the risk of bias tool. 10 The predefined key domains included random sequence generation, allocation concealment, blinding, and other items (ie, efficacy analysis, lost to follow-up, intention-to-treat analysis, and statistical analysis).
statistical analysis
All outcomes were pooled by using RevMan 5.3 software (Nordiac Cochrane Center, Copenhagen, Denmark; http:// www.cochrane.org/). For dichotomous data, risk ratio (RR) was calculated with 95% confidence intervals (CIs). On the other hand, in case of continuous data, we used weighted mean difference (WMD) with 95% CIs. We calculated the I 2 statistic to estimate heterogeneity. If I 2 was 50%, we chose fixed-effect model with the analyses of the Mantel-Haenszel method; otherwise, the random-effect model was adopted.
Results
literature search and study characteristics
A total of 859 records were identified by our initial search. According to title and abstract, we excluded 825 records (irrelevant, annual meeting, animal, duplicates). Finally, we excluded 29 records and confirmed five studies that met the inclusion criteria by two investigators screening full-text articles. The flow of study search and selection is shown in Figure 1 . Five studies were randomized, double-blind, placebocontrolled trials. These included two fixed-dose trials 11, 12 and three flexible-dose trials. [13] [14] [15] Trial durations ranged from 8 to 10 weeks. A total of 2,637 patients were randomized to the levomilnacipran ER group and placebo group, 2,623 patients were used for safety analyses and 2,598 patients were used for modified intent-to-treat and efficacy analyses (1,032 were randomized to placebo and 1,566 to the levomilnacipran ER group). The basic characteristics of the study are listed in Table 1 .
Quality assessment
All eligible studies described the generation of the randomization sequence. However, allocation concealment was unclear in one study.
14 All studies were at least double blind.
Five studies reported adequate intention-to-treat analysis. [11] [12] [13] [14] [15] Loss to follow-up was minimal and balanced in the five trials. Details of risk of bias assessment are shown in Table 2 . (Figure 2) . In a sensitivity analysis, pooling the data on MADRS showed that the overall estimate was not impacted by excluding a phase II study 15 Figure 3 ). response rate and remission rate Levomilnacipran ER had a greater improvement in the MADRS response rate compared with placebo (40 mg: RR Figure 1 The flow of the study search and selection. Figure 5 ) for 40-120 mg.
MaDrs total score
safety and tolerability
Compared with placebo, the overall rate of discontinuation and discontinuation due to AEs was higher for levomilnacipran ER ( Table 3) . Incidences of AEs (erectile dysfunction, delay in ejaculation, tachycardia, nausea, hedache, dry mouth, increase in heart rate) were higher for levomilnacipran ER ( Table 3 ). The incidences of suicidal ideation and suicidal behavior were similar between the two groups ( Table 4 ). In the five eligible studies, based on the Fridericia correction (QTcF), there was no QTc prolongation. None of the patients met potentially clinically significant criteria for PR (250 milliseconds), QTcB (500 milliseconds), or QTcF (500 milliseconds) interval. Based on the number of men in the safety population. Bold numbers are considered statistically significant. Abbreviations: CI, confidence interval; AE, adverse event.
Discussion
In our systematic review and meta-analysis, levomilnacipran ER resulted in reduction in the MADRS total score and SDS total score compared with placebo. Levomilnacipran ER has a unique pharmacological activity and is relatively more selective for norepinephrine reuptake inhibition than serotonin reuptake inhibition. 6 The strong noradrenergic component of antidepressant may be especially effective in improving symptoms related to functioning. 16 ). Additionally, it has some advantages over TCAs in terms of discontinuation due to AEs and the rates of AEs. 25 Levomilnacipran is the levo enantiomer of milnacipran. Regulatory guidelines in the US and Europe recommend development of the enantiomers over racemates where appropriate. 26 Given the favorable pharmacokinetic and pharmacodynamic characteristics of enantiomeric formulation, levomilnacipran ER may be more effective than milnacipran. However, head-to-head trials with levomilnacipran ER and milnacipran have not been performed.
limitations
There were also limitations in this meta-analysis. First, our analysis highlighted the overall short-term safety and efficacy of levomilnacipran ER; the extended period is needed to understand the long-term benefits and risks. Second, agomelatine is another novel antidepressant that does not induce 5-HT2A stimulation, having a more favorable adverse-effect profile compared with the common SSRIs. 27 However, the lack of head-to-head trials limited the ability to compare levomilnacipran ER with agomelatine or other antidepressants. Future studies will be needed to compare levomilnacipran ER with other antidepressants. Third, strict inclusion and exclusion criteria might have limited these findings to a smaller population. Future larger studies designed to evaluate patients with recurrent or treatment-resistant depression are necessary. Fourth, levomilnacipran ER appears to display greater noradrenergic activity at a lower dose and increasing effects on serotonergic neurotransmission as the dose increases. 28 However, our study did not detect doseresponse effects, since most of the clinical studies used flexible dosing.
Conclusion
This meta-analysis indicated that levomilnacipran ER might be safe and effective for short-term treatment of MDD. However, large, multicenter, randomized controlled trials of recovery from MDD. Symptomatic improvement may provide an early sign of treatment response, and functional improvement may be a better indicator of meaningful change. 18 The MADRS total score 2 points for the test group versus placebo, which suggests that symptomatic improvement is clinically relevant. 19 A significant improvement in SDS means that function is improved. 9 In our study, the MADRS score exceeded 3.36 points for levomilnacipran ER compared with placebo. In addition, a significant difference in favor of levomilnacipran ER was also observed in the SDS total score. These observations may indicate that levomilnacipran ER might provide both symptomatic and functional efficacies.
If the response rate far exceeds the 10% average advantage for drug versus placebo, it is generally regarded as sufficient to establish antidepressant treatment advantage. 20 In our results, the rate of MADRS response was significantly greater for levomilnacipran ER versus placebo.
Most likely due to levomilnacipran ER related to the twofold greater potency for norepinephrine reuptake inhibition compared with serotonin reuptake inhibition, 6 levomilnacipran ER was generally well tolerated in the five eligible studies, which was consistent with the results of 48-week open-label study and the 39-week relapse prevention study. 21, 22 However, compared with placebo, most incidences of AEs were higher for levomilnacipran ER. The five eligible studies showed that the common AEs were nausea, delay in ejaculation, erectile dysfunction, tachycardia, headache, and increase in heart rate. Pulse rate and blood pressure increases were greater for levomilnacipran ER versus placebo. Greater increase in QTcB was observed in the levomilnacipran ER group compared with placebo, which was consistent with increases in heart rate. The mean QTcF changes were small in both groups. In suicidal ideation and suicidal behavior, levomilnacipran ER and placebo patients had similar numbers.
Milnacipran was approved for the management of fibromyalgia in the US and for the treatment of MDD in many countries outside the US. 23, 24 A earlier systematic review had shown that there was no difference in the overall are still needed to assess the safety and efficacy of levomilnacipran ER. Furthermore, head-to-head trials comparing levomilnacipran ER with other antidepressants are needed to confirm the conclusion.
